SG Americas Securities LLC Buys 30,240 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

SG Americas Securities LLC grew its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 115.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,389 shares of the company’s stock after acquiring an additional 30,240 shares during the quarter. SG Americas Securities LLC owned about 0.08% of Zentalis Pharmaceuticals worth $171,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ZNTL. China Universal Asset Management Co. Ltd. raised its stake in shares of Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares during the period. Carson Advisory Inc. raised its stake in Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after acquiring an additional 8,800 shares during the period. Erste Asset Management GmbH purchased a new position in Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals in the third quarter worth approximately $37,000. Finally, 49 Wealth Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 81.7% in the third quarter. 49 Wealth Management LLC now owns 22,558 shares of the company’s stock worth $83,000 after purchasing an additional 10,145 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ZNTL shares. HC Wainwright cut their price objective on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. UBS Group decreased their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Guggenheim cut their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, Wells Fargo & Company decreased their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.24.

Insider Activity

In other news, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction on Friday, January 31st. The stock was bought at an average price of $1.72 per share, with a total value of $103,200.00. Following the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. The trade was a 67.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.60% of the company’s stock.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $1.92 on Monday. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $18.07. The company has a market cap of $136.82 million, a PE ratio of -0.77 and a beta of 1.81. The business has a 50-day simple moving average of $2.77 and a two-hundred day simple moving average of $3.18.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.